SLC5A2 and chronic kidney disease: Early treatment with SGLT2 inhibitors following an AMI has been shown to be safe, to improve cardiometabolic health [18], as well as to reduce HHF rates in patients with risk factors such as T2DM, HF, and CKD [19].